Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

Patient-derived organoids (PDOs) of lung cancer has been recently introduced,reflecting the genomic landscape of lung cancer. However, clinical relevance of advanced lung adenocarcinoma organoids remains unknown. Here, we examined the ability of PDOs to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.